FDA panel endorses Xarelto

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 15-2 on Thursday that data for Xarelto rivaroxaban from Johnson & Johnson (NYSE:JNJ) and Bayer (Xetra:BAY) demonstrate a favorable risk-be...